Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial.
D001772:Blood Cell Count; D001792:Blood Platelets; D001853:Bone Marrow / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D009504:Neutrophils; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010666:Phenylpropionates / Q000494:pharmacology / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy; D013997:Time Factors
D010666:Phenylpropionates; D009277:Nandrolone; D003520:Cyclophosphamide